Vol. 45 (4): 655-657, July – August, 2019
doi: 10.1590/S1677-5538.IBJU.2019.04.02
EDITORIAL
Marco Moschini 1,2, Armando Stabile 1,3, Agostino Mattei 2, Francesco Montorsi 3, Xavier Cathelineau 1, Rafael Sanchez-Salas 1
1 Department of Urology, L’Institut Mutualiste Montsouris, Université Paris Descartes, Paris, France; 2 Department of Urology, Luzerner Kantonsspital, Spitalstrasse, 6000 Luzern, Switzerland; 3 Department of Urology, Urological Research Institute, San Raffaele Scientific Institute, Milan, Italy
Bladder cancer (BCa) is the second most common genitourinary malignancy with 81,190 estimated new diagnoses for 2018 in the United States alone (1). Radical cystectomy (RC) with bilateral pelvic lymph node dissection (PLND) and perioperative chemotherapy is the standard treatment recurrent high risk non-muscle invasive and for muscle invasive BCa (2). However, RC as well as perioperative chemotherapy represent a complex procedure associated with high perioperative morbidity and mortality as a consequence also of the characteristics of the population which is generally affected by multiple comorbidities when compared to other surgical procedures (3, 4).
